FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

12 letters match. Newest first.

  1. Curia New York, Inc.

    FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.

    High risk
  2. Ava Inc.

    FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.

    High risk
  3. Unipack LLC

    FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.

    High risk
  4. Taizhou Kangping Medical Science and Technology Co., Ltd.

    FDA warns Taizhou Kangping about over-the-counter drugs labeled sterile that were not sterilized.

    High risk
  5. NWL Netherlands Services B.V.

    FDA cites NWL Netherlands drug plant for inadequate microbial investigations, missing component identity testing, and weak lab data controls.

    High risk
  6. LCC Ltd.

    FDA warned LCC Ltd. over manufacturing-quality failures, contamination testing gaps, discarded lab data, and unapproved mouthwash drugs.

    High risk
  7. Analytical Food Laboratories, Inc.

    FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.

    High risk
  8. GFA Production Xiamen Co., Ltd.

    GFA Production Xiamen failed CGMP for drugs, including process validation, cleaning, and lab controls.

    High risk
  9. Grupo Quimico SRL

    FDA warns Uruguay contract testing lab Grupo Quimico over data integrity failures, including unreported failing HPLC results.

    High risk
  10. Westwood Laboratories LLC

    FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.

    High risk
  11. Centaur Pharmaceuticals Private Ltd.

    FDA warns Centaur Pharmaceuticals over manufacturing practice failures in active ingredients, including records and cleaning.

    High risk
  12. Green Wave Analytical, LLC

    FDA warned Green Wave Analytical, a contract drug testing lab, over quality violations and its denied inspection access.

    High risk